GT Biopharma Files 8-K on Material Agreements & Equity Sales
Ticker: GTBP · Form: 8-K · Filed: May 13, 2025 · CIK: 109657
| Field | Detail |
|---|---|
| Company | Gt Biopharma, INC. (GTBP) |
| Form Type | 8-K |
| Filed Date | May 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, corporate-action
TL;DR
GT Biopharma filed an 8-K detailing new material agreements, equity sales, and changes to security holder rights.
AI Summary
GT Biopharma, Inc. filed an 8-K on May 13, 2025, reporting on several material events as of May 12, 2025. These include entering into a material definitive agreement, unregistered sales of equity securities, material modifications to security holder rights, and amendments to its articles of incorporation or bylaws. The filing also includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate actions by GT Biopharma, including potential new agreements and equity transactions that could impact its financial structure and shareholder rights.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can introduce financial and operational risks.
Key Players & Entities
- GT Biopharma, Inc. (company) — Registrant
- May 12, 2025 (date) — Date of earliest event reported
- May 13, 2025 (date) — Filing date
FAQ
What is the nature of the material definitive agreement entered into by GT Biopharma?
The filing does not specify the details of the material definitive agreement, only that one was entered into as of May 12, 2025.
What type of equity securities were sold in the unregistered sale?
The filing indicates unregistered sales of equity securities occurred, but does not specify the type or amount of securities sold.
What specific modifications were made to the rights of security holders?
The filing states there were material modifications to the rights of security holders, but the specific changes are not detailed in this summary.
Are there any amendments to GT Biopharma's articles of incorporation or bylaws mentioned?
Yes, the filing indicates amendments to the articles of incorporation or bylaws as of May 12, 2025.
What is the fiscal year end for GT Biopharma?
GT Biopharma's fiscal year ends on December 31st.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 13, 2025 regarding GT Biopharma, Inc. (GTBP).